Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (3)

2021

  1. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2019

  1. Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients

    Journal of Clinical Medicine, Vol. 8, Núm. 12

2006

  1. Molecular profiling of computed tomography screen-detected lung nodules shows multiple malignant features

    Cancer Epidemiology Biomarkers and Prevention, Vol. 15, Núm. 2, pp. 373-380